INmune Bio (NASDAQ:INMB) Stock Price Down 2% – Should You Sell?

INmune Bio, Inc. (NASDAQ:INMB) shares traded down 2% on Tuesday. The company traded as low as $1.94 and last traded at $1.96. Approximately 286,453 shares were traded during trading, a decline of 14% from the average daily volume of 333,381 shares. The stock had previously closed at $2.00.

Analysts Set New Price Targets

Several research firms have issued reports on INMB. Weiss Ratings raised shares of INmune Bio from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, August 19th. Wall Street Zen raised shares of INmune Bio from a “sell” rating to a “hold” rating in a research report on Saturday, August 8th. One equities research analyst has rated the stock with a Strong Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy”.

INmune Bio Trading Down 1.0%

The firm has a market capitalization of $53.56 million, a P/E ratio of -2.88 and a beta of 0.93. The stock has a 50-day simple moving average of $2.12 and a two-hundred day simple moving average of $1.68.

INmune Bio (NASDAQ:INMB) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.05) EPS for the quarter, beating the consensus estimate of ($0.21) by $0.16.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Bank of New York Mellon Corp bought a new stake in shares of INmune Bio in the 2nd quarter valued at about $35,000. Focus Partners Advisor Solutions LLC purchased a new position in INmune Bio during the second quarter valued at approximately $71,000. GSA Capital Partners LLP purchased a new position in INmune Bio during the second quarter valued at approximately $134,000. Ieq Capital LLC bought a new position in INmune Bio in the second quarter worth approximately $134,000. Finally, BlackRock Inc. bought a new position in INmune Bio in the second quarter worth approximately $508,000. Hedge funds and other institutional investors own 12.72% of the company’s stock.

About INmune Bio

INmune Bio, Inc is a clinical-stage biotechnology company developing treatments that target the innate immune system. The company focuses on therapies designed to address chronic inflammation and immune dysfunction associated with cancer, neurodegenerative diseases and other serious medical conditions.

Its lead technology, XPro, is an engineered form of tumor necrosis factor (TNF) designed to selectively neutralize soluble TNF while preserving transmembrane TNF activity. INmune Bio is studying XPro in conditions involving neuroinflammation, including Alzheimer’s disease and treatment-resistant depression.